Finance analyst: Eli Lilly deals hard blow to Novo Nordisk with new data

While many Danish analysts were not overly concerned by Eli Lilly's novel data for tirzepatide as a rival to Novo Nordisk's semaglutide, financial analyst Jefferies sees the new data as a considerable threat against Novo Nordisk's market shares.
Photo: Darron Cummings/AP/Ritzau Scanpix
Photo: Darron Cummings/AP/Ritzau Scanpix

US investment banking company and financial analyst Jefferies views data from US pharmaceutical company Eli Lilly's recent studies with tirzepatide up against Danish firm Novo Nordisk's semaglutide as highly convincing. In-house analyst Peter Welford thinks Novo Nordisk's salespeople will have a hard time contesting tirzepatide's superior effect, since the new data comes from a direct comparison study, known as a head-to-head.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading